European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 
Allocate·a game built on the record

Money decides which mental health medicines reach people. Your turn.

1Drag a coin onto a drug2See the patients, and where they are3See the odds, and the wait
Who it's forDepressive disorders · 21 millionAnxiety disorders · 25 million
0 patients in European trials you back

Each dot is a million people in the EU. Drop a coin and light up the ones your drug is being tested for.

People can have more than one condition. Do not add these up.

Your money
10 × €10m
€10m
€10m
€10m
€10m
€10m
€10m
€10m
€10m
€10m
€10m
All ten placed. Tap a coin in a row to take it back.Start over

A simulation for education. No money is invested. Not investment advice or a recommendation. The medicines shown are investigational and not authorised in the EU. Not medical advice. Psychedelic Brief has no financial relationship with the companies shown.

Hinweis auf Deutsch

Eine Simulation zu Bildungszwecken. Es wird kein Geld investiert. Keine Anlageberatung und keine Empfehlung. Die gezeigten Arzneimittel befinden sich in der klinischen Prüfung und sind in der EU nicht zugelassen. Keine medizinische Beratung. Psychedelic Brief steht in keiner finanziellen Beziehung zu den gezeigten Unternehmen.

COMP360
Psilocybin, Compass · Phase 3 complete, US filing under way · No European partner
126 patients in 9 EU states
DT120
LSD, Definium · Phase 3, 3 of 4 trials positive · No European partner
201 patients in 4 EU states
HLP003
Deuterated psilocin, Helus · Phase 3, results guided Q4 2026 · No European partner
at least 131 patients in 5 EU states
GH001
5-MeO-DMT, GH Research · Phase 2b done, Phase 3 guided 2026 · No European partner
81 patients in 5 EU states
Hospital trials
Psilocybin and MDMA, 5 hospitals · Phase 2 · Grants, not equity
156 patients in 4 EU states
BPL-003
5-MeO-DMT · bought by Lilly, $3.8bn
Taken
Status as of 5 Oct 2026
Share of new EU medicines available to patients80% and up55 to 79%40 to 54%under 40%not in our dataEFPIA W.A.I.T. 2025, medicines authorised 2021 to 2024. Industry survey.
The odds, and the wait

Drop a coin. Here you will see how often drugs at that stage have historically been approved, and how long approved medicines take to reach patients in Europe.

You
0EU countries
Drop a coin to begin.
Pharma, real deals
$8.2bn
Headline value of deals signed by Lilly, AbbVie, Otsuka. $0 to the four unpartnered assets on your board.
Where readers put their coins
Opens at 50 players
What readers did, shown with the count and the date. Not a forecast, not odds.
0of 27 EU countries
Drop a coin to begin.

What moves your map next

Dated events from registries and filings. Company guidance is marked as such. Where we have made a call, agree or disagree; when it resolves, you see how the readers who disagreed did against us.

  • by 31 Dec 2026COMP360Compass discloses completion of its rolling NDA submission.
    Our call: it happens.
  • not yet datedDT120Ascend, the fourth Phase 3, reads out. Three of four positive so far.Call opens when dated
  • Q4 2026HLP003APPROACH Phase 3 topline. Company guidance.Call opens when dated
  • 2026GH001Pivotal programme starts. Company guidance.Call opens when dated
  • rollingHospital trialsRecruitment and results posted on CTIS.No call
Our record:2right1wrong12openThe call is ours. The verdict is public.The ledger

Your Europe is empty.

Every coin lights up the countries where that drug is being tested on patients right now.

When a trial on your map moves, the Tuesday issue tells you first.

Free. One email, Tuesday 11:00.

For funds and pipelines

Running diligence?

Every row on this board traces back to a registry or a filing. Bring the European asset, deal or trial you are looking at. We bring the record.

Book a 20-minute briefing
Sources and method
PeopleIHME estimate for 2016, EU-28 including the UK, via OECD Health at a Glance: Europe 2018.
PatientsPlanned participants per EU member state in CTIS and ClinicalTrials.gov, read 5 Oct 2026. HLP003 is a floor. Stages, sponsors and countries from registries and company filings.
OddsBIO, Informa and QLS, Clinical Development Success Rates 2011 to 2020. Psychiatry, US FDA, company-sponsored programmes. A base rate, not a forecast.
AccessEFPIA W.A.I.T. 2025, medicines authorised 2021 to 2024. No EU marketing application found for any asset shown.

A simulation for education. No money is invested. Not investment advice, not a recommendation, not medical advice. Psychedelic Brief has no financial relationship with the companies shown.

Hinweis auf Deutsch

Eine Simulation zu Bildungszwecken. Es wird kein Geld investiert. Keine Anlageberatung und keine Empfehlung. Die gezeigten Arzneimittel befinden sich in der klinischen Prüfung und sind in der EU nicht zugelassen. Keine medizinische Beratung. Psychedelic Brief steht in keiner finanziellen Beziehung zu den gezeigten Unternehmen.